Education
About Us
Working with TipRanks
Follow Us
Amplia Therapeutics Ltd. (AU:ATX)
ASX:ATX
ATX Stock Chart & Stats
AU$0.14
<AU$0.01(2.33%)
At close: 4:00 PM EST
AU$0.14
<AU$0.01(2.33%)
Day’s Range― - ―
52-Week RangeAU$0.05 - AU$0.43
Previous CloseN/A
Volume274.48K
Average Volume (3M)525.22K
Market Cap
AU$62.85M
Enterprise ValueAU$35.36M
Total Cash (Recent Filing)AU$29.16M
Total Debt (Recent Filing)AU$381.42K
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding513,071,660
10 Day Avg. Volume444,673
30 Day Avg. Volume525,217
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.02
Price to Sales (P/S)5.68
P/FCF Ratio-3.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsGross margins above 90% indicate very low cost of goods sold relative to revenues. For a development-stage biotech this durable efficiency means any future licensing or partner revenues can convert to cash for R&D and operations, improving capital efficiency as programs scale.
Conservative Balance Sheet / Low LeverageA low debt-to-equity ratio and healthy equity position give Amplia lasting financial flexibility. Conservative leverage provides a buffer against clinical setbacks, supports continued trial investment, and reduces near-term refinancing pressure compared with highly leveraged peers.
Focused Lead Asset And Clear Development StrategyA focused pipeline centered on narmafotinib (AMP945), a targeted FAK inhibitor, provides a clear strategic development path. Concentrating resources on a lead oncology asset can improve trial efficiency and make the program more attractive for partnerships or licensing if clinical data are positive.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flows reflect ongoing cash burn that is typical but consequential. Continued outflows over months force the company to seek external financing or partnerships, increasing dilution risk and potentially constraining development timelines or program scope.
Ongoing Losses And Negative ProfitabilitySustained negative net, EBIT and EBITDA margins show the company is not yet profitable. Negative profitability depresses returns on equity and ensures ongoing reliance on capital markets or partners to fund operations, elevating execution risk if funding conditions deteriorate.
Single-Asset Concentration RiskConcentration on a single lead candidate creates binary clinical and commercial risk. A setback for AMP945 would materially impair revenue prospects and strategic options given limited diversification, increasing dependence on successful trials or external partnerships to sustain the business long term.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.05 and its highest was AU$0.42 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$62.85M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 98 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on Nov 27, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Overvalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,071,660 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $153.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
-27.39%
Trailing 12-Months
Asset Growth
199.58%
Trailing 12-Months
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics (ATX) is a biotechnology company focused on developing innovative therapies for the treatment of fibrotic diseases and cancer. The company specializes in the discovery and development of small molecule drugs that target the underlying biological processes driving these conditions. Amplia's core products include its lead drug candidate, which is designed to inhibit specific pathways involved in fibrosis, thereby offering potential benefits for patients suffering from these debilitating diseases.
Technical Analysis
Noxopharm Ltd.
―
Nanollose Ltd.
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---